La Jolla Pharmaceutical Company (LJPC) financial statements (2021 and earlier)

Company profile

Business Address 4747 EXECUTIVE DRIVE, SUITE 240
SAN DIEGO, CA 92121
State of Incorp. CA
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2188173916612649
Cash and cash equivalents2188173916612649
Receivables631    
Inventory, net of allowances, customer advances and progress billings622    
Inventory622    
Prepaid expense1      
Other undisclosed current assets3453212
Total current assets:3697181946712850
Noncurrent Assets
Operating lease, right-of-use asset1 
Property, plant and equipment0182225320
Intangible assets, net (including goodwill)35      
Goodwill20      
Intangible assets, net (excluding goodwill)15      
Restricted cash and investments0111   
Other undisclosed noncurrent assets 15  00 
Total noncurrent assets:36352325320
TOTAL ASSETS:721322041207112951
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities122229171052
Accounts payable34911731
Accrued liabilities69131111
Employee-related liabilities3885210
Deferred rent credit  1
Deferred revenue and credits1   
Other undisclosed current liabilities03     
Total current liabilities:122530191052
Noncurrent Liabilities
Long-term debt and lease obligation0      
Operating lease, liability0 
Liabilities, other than long-term debt4131413   
Deferred revenue and credits13   
Deferred rent credit  14
Other liabilities413     
Other undisclosed noncurrent liabilities144151124    
Total noncurrent liabilities:14816413813   
Total liabilities:160188168311052
Stockholders' equity
Stockholders' equity attributable to parent, including:(88)(56)36886112548
Common stock0000000
Additional paid in capital985977950803661646528
Accumulated deficit(1,077)(1,037)(921)(722)(607)(529)(487)
Other undisclosed stockholders' equity attributable to parent4477777
Total stockholders' equity:(88)(56)36886112548
TOTAL LIABILITIES AND EQUITY:721322041207112951

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues332310 11 
Revenue, net 11 
Cost of revenue
(Cost of Goods and Services Sold)
(8)(2)(2)(2)(1)(1) 
Gross profit:26218(2)00 
Operating expenses(61)(130)(202)(115)(79)(43)(21)
Other undisclosed operating income   211 
Operating loss:(36)(110)(194)(115)(78)(42)(21)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(0) (5)1000
Interest and debt expense(10)(11)(7)    
Net loss:(46)(121)(207)(115)(78)(42)(21)
Other undisclosed net income attributable to parent747    
Net loss available to common stockholders, diluted:(39)(117)(199)(115)(78)(42)(21)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(46)(121)(207)(115)(78)(42)(21)
Other undisclosed comprehensive income      43
Comprehensive income (loss), net of tax, attributable to parent:(46)(121)(207)(115)(78)(42)21

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: